Toplumdan Kazanılmış Komplike Üriner Sistem Enfeksiyonlarında Ampirik Antibiyotik Tedavilerinin Değerlendirilmesi
Abstract
Objectives: Complicated urinary tract infection (UTI) is caused by gram negative bacteria; among them, Escherichia coli is the most common. The increase in antibiotic resistance rates of common agents decreases the empirical treatment options. The aim of this study was to investigate the concordance of empirical antibiotic treatment in complicated UTI patients who were followed up in our clinic in the last two years
Materials and Methods: This study was conducted as a descriptive retrospective study between 01.01.2017 and 01.01.2019. Demographic, laboratory and clinical data of the patients were obtained by scanning files or automation systems. If the microorganism was sensitive to empirical antibiotic treatment the situation was defined as concordance of treatment.
Results: In our study, 102 patient files were examined and 74 were excluded from the study. Of the 28 patients, 19 (67.9%) were male. The mean age of the patients was 58.18±19.98 years. E. coli was the most frequently isolated agent. As empirical treatment cephalosporins and carbapenems were mostly preferred. When all antibiotics are evaluated together, it is seen that 53.6% of the empirical antibiotic treatments are concordance with culture results. The suitability rates for carbapenems and cephalosporins, which are the most commonly used antibiotics, were 46.7% and 60%, respectively.
Conclusion: According to the results of this study, our empirical treatment choices are suitable in the treatment of complicated UTI. However, it may be a rational approach to prioritize cephalosporins in similar situations in our center.
Keywords
Urinary Tract Infection, Empirical Antibiotic Treatments, Concordance
Ethical Statement
Etik Kurul Onayı: Gülhane Eğitim ve Araştırma Hastanesi Yerel etik Kurulu’ndan 12.02.2019 tarih ve 19/22 no’lu etik kurul onayı alınmıştır.
References
- 1. Bader MS, Loeb M, Brooks AA. An uptodate on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129: 242-58.
- 2. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:103-120.
- 3. Bosch-Nicolau P, Falcó V, Viñado B, et al. A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis. Antimicrob Agents and Chemother. 2017:61.
- 4. Greenhouse I, Babushkin F, Finn T, et al. Long-term outcomes of inappropriate antibiotic therapy for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a retrospective cohort study. Diagn Microbiol Infect Dis. 2017;89:222-229.
- 5. Benítez-Sala R, Medina-Polo J, Justo-Quintas J, et al. Infections related to healthcare in patients hospitalized in a Urology service: resistance patterns and adequacy of empirical antibiotic treatment as a prognostic factor. Actas Urol Esp. 2019;43:151-157.
- 6. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-ß-lactamase producing Escherichia coli. Antimicrobial Agents And Chemotherapy. 2010: 4006-4008.
- 7. Coskun O, Erdem H, Avci A. Management of community acquired acute bacterial cystitis in Turkey. Turk J Med Sci. 2011; 41:149-157.
- 8. Pullukcu H, Aydemir S, Isikgoz-Tasbakan M, et al. Susceptibility of extendedspectrum beta-lactamase-producing Escherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim-sulfamethoxazole. Turk J Med Sci. 2008;38:175-180.
- 9. Arman D, Agalar C, Dizbay M, et al. Community acquired lower urinary tract infections in primary care: causative agents and antimicrobial susceptibility. Mediterr J Infect Microb Antimicrob. 2012;1:1-8.
- 10. Dolgova SS, Padial PP, Morales AJ, et al. Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program. J Infect Public Health. 2019:1195.